• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

    11/12/24 10:32:12 AM ET
    $JANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JANX alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.3 JANUX THERAPEUTICS INC COMMON STOCK Cusip #47103J105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #47103J105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,823,767 Item 6: 0 Item 7: 7,824,674 Item 8: 0 Item 9: 7,824,674 Item 11: 14.999% Item 12: HC Cusip #47103J105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,824,674 Item 8: 0 Item 9: 7,824,674 Item 11: 14.999% Item 12: IN Item 1(a). Name of Issuer: JANUX THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO, CA 92130 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 47103J105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,824,674 (b) Percent of Class: 14.999% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,824,674 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of JANUX THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of JANUX THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of JANUX THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $JANX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JANX

    DatePrice TargetRatingAnalyst
    7/11/2025$65.00Outperform
    Raymond James
    12/3/2024$82.00 → $100.00Buy
    BTIG Research
    12/3/2024$63.00 → $70.00Buy
    H.C. Wainwright
    11/22/2024$79.00Outperform
    Leerink Partners
    10/24/2024$69.00Buy
    UBS
    9/6/2024$70.00Buy
    Stifel
    5/30/2024$47.00Sector Perform
    Scotiabank
    3/21/2024$62.00Buy
    BTIG Research
    More analyst ratings

    $JANX
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.

      SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)

      7/17/25 7:54:40 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Janux Therapeutics, Inc. (0001817713) (Filer)

      6/13/25 4:35:34 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.

      SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      5/14/25 12:25:43 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Janux Therapeutics with a new price target

      Raymond James initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $65.00

      7/11/25 8:13:15 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research reiterated coverage on Janux Therapeutics with a new price target

      BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously

      12/3/24 7:52:53 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously

      12/3/24 7:50:21 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. bought $25,342,965 worth of shares (824,041 units at $30.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      3/7/25 6:05:32 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      10/22/24 4:20:04 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      11/15/23 4:48:17 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

      7/17/25 4:30:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ra Capital Management, L.P. was granted 3,750 shares (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:33:08 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dobmeier Eric was granted 3,750 shares, increasing direct ownership by 60% to 9,981 units (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:30:18 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gujrathi Sheila was granted 3,750 shares, increasing direct ownership by 3% to 118,889 units (SEC Form 4)

      4 - Janux Therapeutics, Inc. (0001817713) (Issuer)

      6/13/25 7:30:17 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:24:38 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:17:06 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.

      SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)

      11/14/24 4:01:49 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Leadership Updates

    Live Leadership Updates

    See more
    • Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

      PSMA-TRACIr designed to be combined with potentially best-in-treatment asset, JANX007, and provide CD28 co-stimulation to further differentiate depth and durability of patient responses. TROP2-TRACTr adds first-in-class and best-in-class opportunity targeting multiple solid tumors with preclinical data supporting differentiated safety and efficacy potential. CD19-ARM displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, advancing toward first-in-human trials anticipated to begin in the first half of 2026. Webcast to be held today at 1:30 PM PT. Janux Therape

      7/24/25 4:05:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

      Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that it will host a virtual R&D Day at 1:30 PM PT on Thursday, July 24, 2025. The event will include a presentation from management highlighting product candidates identified from its preclinical pipeline to move into clinical trials. These previously undisclosed preclinical programs utilize Janux's expertise and platform technologies to potentially address significant unmet medical needs.

      7/17/25 4:30:00 PM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

      Ms. Doyle brings more than two decades of corporate strategy and business development experience across biotech, pharma, and venture ecosystems Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. "Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at J

      5/15/25 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JANX
    Financials

    Live finance-specific insights

    See more
    • Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

      Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica

      7/17/23 8:00:00 AM ET
      $JANX
      Biotechnology: Pharmaceutical Preparations
      Health Care